Chemours
CC
Market cap $1.85B

12.38 USD

-0.11

0.88%

At close Apr 30, 4:00 PM EDT

After hours

11.52

-0.86

6.95%

1 day

-0.88%

5 days

3.25%

1 month

-8.50%

3 months

-36.02%

6 months

-32.39%

Year to date

-25.91%

1 year

-53.72%

5 years

5.54%

10 years

-25.02%

About: The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

Employees: 6,000

Materials Specialty Chemicals

0

Funds holding %

of 7,425 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

268% more call options, than puts

Call options by funds: $71.5M | Put options by funds: $19.4M

49% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 53

40% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 101

3.9% more ownership

Funds ownership: 80.42% [Q3] → 84.32% (+3.9%) [Q4]

4% more funds holding

Funds holding: 418 [Q3] → 434 (+16) [Q4]

13% less capital invested

Capital invested by funds: $2.44B [Q3] → $2.13B (-$310M) [Q4]

17% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 5 (-1) [Q4]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

29%

upside

Avg. target

$21

70%

upside

High target

$27

118%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

Truist Securities Peter Osterland 36% 1-year accuracy 5 / 14 met price target	78%upside $22	Buy Maintained	14 Apr 2025
Barclays Michael Leithead 29% 1-year accuracy 6 / 21 met price target	29%upside $16	Equal-Weight Maintained	1 Apr 2025
Mizuho John Roberts 22% 1-year accuracy 8 / 37 met price target	53%upside $19	Outperform Upgraded	27 Mar 2025
BMO Capital John McNulty 20% 1-year accuracy 9 / 44 met price target	118%upside $27	Outperform Maintained	19 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CC published over the past 30 days

Zacks Investment Research

Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

Wall Street's Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Weigh In On 3 Materials Stocks With Over 7% Dividend Yields

Chemours Announces Dates for First Quarter 2025 Earnings Release and Webcast Conference Call

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Dates for First Quarter 2025 Earnings Release and Webcast Conference Call.

Chemours Announces Dates for First Quarter 2025 Earnings Release and Webcast Conference Call

Zacks Investment Research

Why Is Chemours (CC) Down 14% Since Last Earnings Report?

Chemours (CC) reported earnings 30 days ago. What's next for the stock?

Why Is Chemours (CC) Down 14% Since Last Earnings Report?

Zacks Investment Research

Chemours Forms Partnership With Energy Fuels to Establish Supply Chain

CC & Energy Fuels team up to expand rare earth and critical mineral supply chains in the U.S. domestic market.

Chemours Forms Partnership With Energy Fuels to Establish Supply Chain

Energy Fuels and Chemours Forming Strategic Alliance to Create a Domestic Supply Chain of Critical Minerals for the United States

DENVER , March 18, 2025 /PRNewswire/ - Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) and The Chemours Company (NYSE: CC) today announced they are forming a strategic alliance to expand the companies' existing relationship to enhance U.S. domestic rare earth and critical mineral supply chains to meet increasing demand. The alliance will capitalize on the complementary geographic and operational synergies of both organizations.

Energy Fuels and Chemours Forming Strategic Alliance to Create a Domestic Supply Chain of Critical Minerals for the United States

Chemours and Energy Fuels Forming Strategic Alliance to Create a Domestic Supply Chain of Critical Minerals for the United States

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours and Energy Fuels Forming Strategic Alliance to Create a Domestic Supply Chain of Critical Minerals for the United States.

Chemours and Energy Fuels Forming Strategic Alliance to Create a Domestic Supply Chain of Critical Minerals for the United States

Zacks Investment Research

Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial

CC partners with industry leaders to address the data center cooling gap by conducting Opteon 2P50 product trials.

Chemours, NTT DATA & Hibiya Engineering Join Forces for Product Trial

Chemours Joins Forces with NTT DATA and Hibiya Engineering, Ltd. For Full-Scale Opteon™ 2P50 Product Trial

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Joins Forces with NTT DATA and Hibiya Engineering, Ltd. For Full-Scale Opteon™ 2P50 Product Trial.

Chemours Joins Forces with NTT DATA and Hibiya Engineering, Ltd. For Full-Scale Opteon™ 2P50 Product Trial

Zacks Investment Research

Chemours' Earnings Outpace Estimates, Revenues Miss in Q4

CC's sales fall modestly as a drop in pricing is largely offset by a gain in volume, while the currency impact remains unchanged in Q4.

Chemours' Earnings Outpace Estimates, Revenues Miss in Q4

See News Rankings

Charts implemented using Lightweight Charts™